Study on the Tolerability and Pharmacokinetics of HX009 in Patients With Advanced Solid Tumors
Status:
Active, not recruiting
Trial end date:
2024-10-28
Target enrollment:
Participant gender:
Summary
This is an open, multi-dose administration dose exploratory clinical phase I study to
evaluate the safety, tolerability, and PK characteristics of HX009 injection in patients with
advanced solid tumors and to initially measure its antitumor efficacy.